Rhumbline Advisers Purchases 2,209 Shares of Lantheus Holdings Inc (NASDAQ:LNTH)

Rhumbline Advisers grew its position in Lantheus Holdings Inc (NASDAQ:LNTH) by 2.0% during the third quarter, HoldingsChannel reports. The firm owned 115,003 shares of the medical equipment provider’s stock after buying an additional 2,209 shares during the period. Rhumbline Advisers’ holdings in Lantheus were worth $2,883,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Grantham Mayo Van Otterloo & Co. LLC boosted its stake in shares of Lantheus by 154.8% in the 2nd quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 186,800 shares of the medical equipment provider’s stock valued at $5,286,000 after purchasing an additional 113,500 shares during the last quarter. Envestnet Asset Management Inc. bought a new stake in shares of Lantheus in the 2nd quarter valued at $578,000. Marshall Wace LLP acquired a new position in shares of Lantheus during the 2nd quarter valued at $884,000. Price T Rowe Associates Inc. MD lifted its position in shares of Lantheus by 21.3% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 2,225,763 shares of the medical equipment provider’s stock valued at $62,989,000 after acquiring an additional 390,644 shares during the period. Finally, Mackenzie Financial Corp acquired a new position in shares of Lantheus during the 2nd quarter valued at $361,000. 96.23% of the stock is currently owned by institutional investors.

Shares of Lantheus stock traded up $0.19 during trading on Tuesday, reaching $21.72. 2,005 shares of the company traded hands, compared to its average volume of 387,002. The company has a debt-to-equity ratio of 1.84, a current ratio of 2.59 and a quick ratio of 2.08. Lantheus Holdings Inc has a 1-year low of $13.82 and a 1-year high of $29.80. The company has a 50 day moving average price of $20.86 and a 200-day moving average price of $23.94. The firm has a market capitalization of $842.26 million, a PE ratio of 23.02, a P/E/G ratio of 1.79 and a beta of 1.46.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, October 31st. The medical equipment provider reported $0.28 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.07. Lantheus had a net margin of 10.02% and a return on equity of 46.58%. The company had revenue of $85.80 million for the quarter, compared to the consensus estimate of $83.82 million. During the same quarter in the previous year, the company earned $0.24 EPS. Lantheus’s quarterly revenue was down 3.5% compared to the same quarter last year. Equities research analysts expect that Lantheus Holdings Inc will post 1 earnings per share for the current year.

In other Lantheus news, CEO Mary Anne Heino sold 15,590 shares of the company’s stock in a transaction on Friday, September 20th. The shares were sold at an average price of $25.81, for a total transaction of $402,377.90. Following the transaction, the chief executive officer now owns 582,294 shares in the company, valued at $15,029,008.14. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Tudor Brown sold 20,469 shares of the company’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $24.93, for a total transaction of $510,292.17. Insiders have sold a total of 79,510 shares of company stock worth $1,839,531 in the last quarter. 2.60% of the stock is owned by corporate insiders.

A number of research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Lantheus from a “sell” rating to a “hold” rating in a research report on Wednesday, September 25th. CJS Securities upgraded shares of Lantheus from a “market perform” rating to an “outperform” rating in a research report on Friday, August 16th. BidaskClub upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, ValuEngine upgraded shares of Lantheus from a “strong sell” rating to a “sell” rating in a research report on Friday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $29.00.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Recommended Story: Book Value Per Share – BVPS

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings Inc (NASDAQ:LNTH).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.